Press release content from Globe Newswire. The AP news staff was not involved in its creation.
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies ...
TG Therapeutics, Inc.December 10, 2020 GMT
Both
significantly reducing
each of the
U
BLA
Thursday, December 10, 2020
ET
NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Company’s investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide in patients with relapsing forms of multiple sclerosis (RMS). Both studies met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p 0.005 in each trial). Ublituximab treatment resulted in an ARR of 0.10 in each of ULTIMATE I & II, with a relative reduction in ARR of approximately 60% and 50%, respectively, over teriflunomide.